Study of Blood and CSF Lymphocyte Characteristics in MS and CIS Patients
This interventional study planned to enroll 150 participants with Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) to analyze blood and cerebrospinal fluid lymphocytes. No results have been posted, and the study is still in the initial phase with no findings reported yet.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
Understanding the characteristics of lymphocytes in MS and CIS could provide insights into disease mechanisms and potential biomarkers for diagnosis or prognosis.
What this does not prove
No results are available as the study is not completed and only planned enrollments are reported. Without published findings, the actual outcomes remain unknown.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 150 · planned enrolment
- Randomised
- Not applicable
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Trial registrationPathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis ↗
Supporting passages (14)
study phasePhase: Not applicable
study designStudy type: Interventional
subjectsParticipants: people; ages from 18 Years; sex All
sample sizeEnrollment: 150 participants (estimated)
randomizedAllocation: Not applicable
relevant ms typesConditions: Multiple Sclerosis; Clinically Isolated Syndrome
primary endpointPrimary endpoints: Functional and phenotypical characterization of the blood and CSF lymphocytes in MS and CIS patients.
follow upFollow-up: At inclusion (day 0)
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
controlledIntervention model: Single group
interventionInterventions: blood sample; cerebro-spinal fluid
sample size basisEnrollment: 150 participants (estimated)
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.